Press Release – RepliCel Reveals Updated Early Trial Results

Snippet from the press release:

RepliCel Life Sciences Inc. is pleased to report that further analysis of results from its successful first-in-man clinical trial revealed substantial hair growth including seven participants with growth in excess of 10%, including 17.2%, 19.2% and 19.6%. Furthermore, there were no negative health effects.

“The RepliCel TS001-2009 trial was a first-in-man trial with a primary endpoint of safety and this was confirmed emphatically,” stated Dr. Rolf Hoffmann, Chief Medical Officer at RepliCel. “Even though the size of the trial was only powered for safety measures, secondary endpoints were included in interim analysis to give us an early look at efficacy to allow us to better drive the design of the next steps of the clinical development of the RepliCel(TM) procedure,” Dr. Hoffmann concluded.

Read the rest — Further Analysis Reveals Double Digit Hair Growth in RepliCel’s First-in-man Clinical Trial

These are updated results that were announced, but the release goes on to say that the trials will be continuing into August 2013, with results to be announced by the end that year.